Aggregate Reporting

The core analytical chapter that integrates cumulative safety data with efficacy information to determine whether the product's benefits continue to outweigh its risks. This section requires:

• Critical assessment of new safety signals identified during the reporting interval
• Comparison of adverse event frequencies against background population rates
• Evaluation of risk minimization measure effectiveness
• Integration of data from multiple sources including clinical trials, post-marketing surveillance, and published literature

The benefit-risk conclusion directly informs regulatory decisions on label changes, risk management plans, or market withdrawal.

A structured reference listing of all serious adverse events reported cumulatively from the product's development international birth date (DIBD) through the data lock point. This component:

• Organizes events by System Organ Class (SOC) and Preferred Term (PT) using MedDRA hierarchy
• Distinguishes between clinical trial and post-marketing sources
• Provides denominator data for exposure-adjusted incidence rates
• Serves as the foundational dataset for disproportionality analysis

The tabulation enables reviewers to identify patterns in event frequency and distribution across body systems over the product's entire lifecycle.

Comprehensive case-level data appendices that enumerate all serious adverse events and non-serious unlisted events reported during the specific reporting interval. Each listing entry includes:

• Case identifier and reporter type (healthcare professional, consumer, literature)
• Patient demographics (age, sex) and relevant medical history
• Suspect product details including dose, route, and duration
• Event description, seriousness criteria, and outcome
• Causality assessment as reported by the original source

Line listings provide granular transparency, allowing regulators to drill down into individual cases that contribute to aggregate statistics.

A regulatory intelligence section documenting the global approval landscape for the product, including:

• Countries where marketing authorization has been granted, with dates
• Pending applications and regulatory review statuses
• Post-marketing commitments and conditions imposed by authorities
• Significant differences in approved indications across regions
• Any regulatory actions taken during the reporting interval, including suspensions, withdrawals, or non-renewals

This component contextualizes safety data within the product's commercial footprint and alerts sponsors to emerging regulatory trends that may signal safety concerns.

A dedicated section that documents the lifecycle of safety signals identified, evaluated, or closed during the reporting interval. For each signal, the report details:

• The source of detection (routine signal detection, literature, regulatory request)
• Methodology used for evaluation, including disproportionality analysis metrics like PRR, ROR, or EBGM
• Evidence assessed, including temporal relationships and dechallenge/rechallenge data
• The final determination: refuted signal, potential risk, or identified risk
• Resulting actions such as label updates or targeted post-authorization safety studies

This section demonstrates the marketing authorization holder's proactive pharmacovigilance surveillance and risk management capability.

Quantitative estimates of patient exposure used as denominators for incidence rate calculations and to contextualize the volume of adverse event reports. Exposure metrics include:

• Patient-years of exposure estimated from sales data, prescription volumes, or patient registries
• Stratification by indication, age group, and geographic region where feasible
• Clinical trial exposure data with subject counts and person-time
• Methodological limitations and assumptions clearly stated

Accurate exposure data is critical for distinguishing true increases in event frequency from artifacts of growing product utilization. Inadequate exposure estimation can mask or exaggerate safety signals.